Department of Neurology, National Neuroscience Institute (Singapore General Hospital Campus), Singapore.
Ann Acad Med Singap. 2020 Apr;49(4):226-235.
Migraine is one of top 5 medical conditions that contribute to Years Lived with Disability and affects approximately 1 billion people from around the world. To date, preventive treatment and acute therapies for migraine are limited, have undesirable side effects and are poorly tolerated in patients. In the last few decades, considerable advances in our understanding of migraine and its pathophysiology have paved the way for the development of targeted treatment options. Calcitonin gene-related peptide (CGRP) plays an integral role in the neurobiology of migraine, and new classes of drugs that target the CGRP pathway have included gepants and CGRP pathway monoclonal antibodies. Serotonin 5-HT receptor agonists-namely ditans-have also been developed to treat acute migraine. Lastly, non-invasive neuromodulation offers another treatment option for migraine patients who prefer treatments that have fewer side effects and are well tolerated. In this review, we discussed emerging treatment options for migraine that were made available in recent years.
偏头痛是导致残疾年数的前 5 大医学病症之一，影响着全球约 10 亿人。迄今为止，偏头痛的预防治疗和急性治疗方法有限，存在不良副作用，并且在患者中耐受性差。在过去几十年中，我们对偏头痛及其病理生理学的理解取得了重大进展，为开发靶向治疗方法铺平了道路。降钙素基因相关肽 (CGRP) 在偏头痛的神经生物学中起着重要作用，靶向 CGRP 途径的新药包括 gepants 和 CGRP 途径单克隆抗体。5-羟色胺 5-HT 受体激动剂-即 ditans-也被开发用于治疗急性偏头痛。最后，非侵入性神经调节为更喜欢副作用少且耐受性好的治疗方法的偏头痛患者提供了另一种治疗选择。在这篇综述中，我们讨论了近年来出现的偏头痛治疗新选择。
